Get the Stockscreener App
9.71
4.24%
-0.43
After Hours:
9.64
-0.07
-0.72%
Biohaven Ltd stock is traded at $9.71, with a volume of 3.94M.
It is down -4.24% in the last 24 hours and down -0.92% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
See More
Previous Close:
$10.14
Open:
$10.15
24h Volume:
3.94M
Relative Volume:
1.80
Market Cap:
$1.46B
Revenue:
-
Net Income/Loss:
$-738.82M
P/E Ratio:
-1.3951
EPS:
-6.9602
Net Cash Flow:
$-610.15M
1W Performance:
+1.04%
1M Performance:
-0.92%
6M Performance:
+16.43%
1Y Performance:
-57.07%
1-Day Range:
$9.125
$10.78
1-Week Range:
$8.95
$10.78
52-Week Range:
$7.48
$22.22
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.71 | 1.53B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Canaccord Genuity | Buy |
| Feb-06-26 | Initiated | Goldman | Buy |
| Jan-21-26 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Dec-03-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-26-25 | Downgrade | UBS | Buy → Neutral |
| Nov-06-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Nov-05-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Initiated | Citigroup | Buy |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
Biohaven Expands At-The-Market Equity Offering Program - TipRanks
Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program - Stock Titan
Biohaven Ltd. (BHVN) upgraded to buy: Here's why - MSN
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why - Yahoo Finance Australia
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target - TipRanks
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
Biohaven Ltd. Q1 2026 Financial Report: Key Highlights, Financial Statements, and Business Overview - Minichart
RBC Cuts Price Target on Biohaven to $22 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
MSN Money - MSN
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Cuts Target Price to $12 - Moomoo
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks - TipRanks
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed? - simplywall.st
Biohaven Shareholders Back Board, Auditor and Executive Pay - TipRanks
Biohaven files for offering of up to $350 million common sharesSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) expands ATM program to $350M for common shares - Stock Titan
Biohaven (NYSE: BHVN) trims Q1 2026 loss and raises $178.9M - Stock Titan
Biohaven Pharma (BHVN) files mixed shelf - StreetInsider
Biohaven Ltd files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) files shelf to register shares, debt and warrants - Stock Titan
Earnings Flash (BHVN) Biohaven Ltd. Posts Q1 Adjusted Loss $0.69 per Share, Vs. FactSet Est of $-0.83 - Moomoo
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biohaven (NYSE: BHVN) cuts Q1 2026 loss while funding late-stage drug pipeline - Stock Titan
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results - ChartMill
Biohaven (NYSE: BHVN) shareholders back directors, auditors and pay plan - Stock Titan
Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio - simplywall.st
Biohaven Faces Catalyst-Rich 2H 2026 With Multiple Key Readouts Ahead - RTTNews
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Director at Biohaven (NYSE: BHVN) receives 68,693 stock options award - Stock Titan
Director Julia P. Gregory awarded 68,693 Biohaven (BHVN) stock options - Stock Titan
(BHVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN
Biohaven (NYSE:BHVN) Trading Up 5.2%Here's What Happened - MarketBeat
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven Obesity Trial Milestone Puts Focus On Taldefgrobep And Valuation Gap - simplywall.st
Biohaven (NYSE:BHVN) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Biohaven (BHVN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline - simplywall.st
Biohaven Completes Enrollment for Obesity Drug Phase 2 Trial - HarianBasis.co
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN) - Insider Monkey
Spinocerebellar Ataxias Pipeline Advances Toward - openPR.com
Biohaven (NYSE:BHVN) Shares Down 5.7%What's Next? - MarketBeat
Biohaven (BHVN) fuels confidence with encouraging azetukalner data - MSN
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating - Insider Monkey
Responsive Playbooks and the BHVN Inflection - Stock Traders Daily
Here is why Biohaven (BHVN) is among the top healthcare stocks insiders are buying - MSN
Biohaven (NYSE:BHVN) Upgraded by Wall Street Zen to Sell Rating - MarketBeat
Why Biohaven (BHVN) Is Up 10.6% After Bullish Analyst Coverage Of Late-Stage Pipeline Prospects - Sahm
Biohaven Receives 'Moderate Buy' Rating from Analysts - National Today
Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 (BHVN) - Seeking Alpha
Biohaven reports details on discovery of BHV-2100 - BioWorld News
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):